Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy

Inclusion Criteria: * Subject is male or female and 16 years or older. Subjects under 18 years of age may be included only where legally permitted and ethically accepted * Subjects having completed the Treatment Period of an applicable previous BRV study, and have access to the present study * Subject for whom the investigator believes a reasonable benefit from the long-term administration of BRV may be expected * Female subjects without childbearing potential (postmenopausal for at least 2 years, bilateral oophorectomy or tubal ligation, complete hysterectomy) are eligible. Female subjects with childbearing potential are eligible if they use a medically accepted contraceptive method * Subjects must be able to take the oral film-coated tablets of BRV Exclusion Criteria: * Subject has developed hypersensitivity to any components of the Investigational Medicinal Product (IMP) or comparative drugs as stated in the protocol during the course of the prior study * Severe medical, neurological, or psychiatric disorders, or laboratory values that may have an impact on the safety of the subject * Poor compliance with the visit schedule or medication intake in the previous BRV study * Planned participation in any other clinical study of another investigational drug or device during this study * Pregnant or lactating woman * Any medical condition which, in the investigator's opinion, warrants exclusion * Subject has a lifetime history of suicide attempt (including an actual attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response ("Yes") to either question 4 or question 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) at the last visit of the previous study or at the Entry Visit of this study if not completed at the last visit of the previous study